Lilly earnings soar on growth of Mounjaro, Zepbound
With quarterly revenue up 54% from a year ago, Eli Lilly raised it guidance for the year, with the company now expecting revenue in the range of $63 billion to $63.5 billion.
Pharmaceutical
Articles
Lilly expands Zepbound direct-to-patient access through Walmart partnership
Through its LillyDirect pharmacy, Eli Lilly plans to offer steep discounts on single-dose vials of Zepbound by partnering with the nation’s largest retail chain.
Lilly plans $1.2B expansion in Puerto Rico, adding 100 manufacturing jobs
Indianapolis-based Eli Lilly and Co. said the improved facility in Carolina, Puerto Rico, will make orforglipron, Lilly’s highly anticipated weight loss pill.
Lilly partners with Indian company to sell blockbuster weight-loss drug under new name
Per the agreement, the Indianapolis-based drugmaker will continue to manufacture the drug, which India-based Cipla will sell under a new brand name.
Novo, Lilly shares fall as Trump touts ‘much lower’ Ozempic price
Mehmet Oz, head of the Centers for Medicare and Medicaid Services, said talks over the price of weight-loss drugs are still ongoing.
Lilly to spend more than $1B to expand operations in India
Indianapolis-based Eli Lilly and Co. said the investment will strengthen its manufacturing and supply capabilities to support its growing portfolio of drugs.
Drugmakers buoyed as Trump deal eases worst fears on pricing
Shares in Indianapolis-based Eli Lilly and Co. were on the rise Wednesday after President Trump suggested the company would be next up to cut a deal over drug pricing.
Cardinal Health to build automated distribution center in Indianapolis
Employees at the facility will work alongside a robotic storage and retrieval system that can provide real-time information regarding inventory, order fulfillment and material flow.
Trump to announce drug-pricing deal with Pfizer, new ‘TrumpRx’ website
The announcements are part of an effort to secure “Most Favored Nation” pricing deals with pharmaceutical manufacturers, an effort to link U.S. drug prices to the lowest cost of drugs paid by the wealthiest countries.
Trump posts video endorsing CBD for seniors. Researchers urge caution.
The video jolted the cannabis industry, sending stocks soaring and raising hopes that the president will take a permissive approach to marijuana.
Drug made from marijuana reduced back pain in large study
The 800-patient study by a German drugmaker is the latest evidence of the therapeutic properties of cannabis, which remains illegal under U.S. federal law even as most states have made it available for medical or recreational use.
What new tariffs mean for pharmaceuticals, patented drugs
President Donald Trump’s announcement that his administration will impose a 100 percent tariff on patented pharmaceutical products sparked confusion Friday, as government officials, drug companies and trade groups sought clarity on how the levy would be applied.
Eli Lilly plans to make highly anticipated weight-loss pill at new $6.5B Texas plant
The $6.5 billion Houston-area plant is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
Demand for obesity treatments has soared recently, due to unprecedented weight loss provided by regular injections of market leaders Wegovy from Novo Nordisk and Zepbound from Indianapolis-based Eli Lilly and Co.
Weight-loss drugs can cut future health costs. The fight is over who pays now.
Evidence from clinical trials shows that GLP-1s have benefits beyond weight loss, preventing related chronic conditions and ultimately blunting health-plan costs. But the savings might take decades, experts say.
Trial shows Lilly rival’s weight-loss pill could deliver same results as shots as companies race to market
Ahead of decisions by the FDA, both Novo Nordisk and Eli Lilly are readying production for their weight-loss pills, having been unable to keep up with demand for their shots that exploded in popularity.
Lilly’s GLP-1 pill beats older Novo diabetes drug in head-to-head trial
Eli Lilly and Co. and Novo Nordisk have been locked in a fierce battle to control the obesity market, which is projected to reach $100 billion by the end of the decade.
Eli Lilly to build $5B plant in Virginia—first of 4 U.S. sites to be named this year
Indianapolis-based Lilly said the new plant would create more than 650 jobs in Virginia for engineers, scientists, operations personnel and lab technicians, as well as 1,800 construction jobs.
Health insurance premiums poised to spike over drug costs, tariff threats
In explaining the rising prices, insurers and employers point to two recent factors: the tariffs on pharmaceutical imports and the high cost of new obesity treatments.
Trump’s plan for drug advertising crackdown faces many hurdles
President Donald Trump signed a memo Tuesday that directs the FDA and other agencies to step up enforcement against ubiquitous prescription drug ads on TV, websites and social media.